Elizabeth Fox

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. ncbi Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, 3501 Civic Center Boulevard, CTRB 4016, Philadelphia, Pennsylvania, USA
    Oncologist 17:321-e329. 2012
  2. ncbi Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, 3501 Civic Center Boulevard, CTRB 4016, Philadelphia, Pennsylvania, USA
    Oncologist 17:321. 2012
  3. ncbi The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA 19104, USA
    J Neuroimmunol 223:138-40. 2010
  4. ncbi A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology CTRB4016, 3501 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Clin Oncol 28:5174-81. 2010

Detail Information

Publications4

  1. ncbi Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, 3501 Civic Center Boulevard, CTRB 4016, Philadelphia, Pennsylvania, USA
    Oncologist 17:321-e329. 2012
    ..The rate of enrollment, rather than the statistical design, had a significant effect on the trial duration...
  2. ncbi Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, 3501 Civic Center Boulevard, CTRB 4016, Philadelphia, Pennsylvania, USA
    Oncologist 17:321. 2012
    ..The primary objective was to determine the objective response rate using response evaluation criteria in solid tumors (RECIST)...
  3. ncbi The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA 19104, USA
    J Neuroimmunol 223:138-40. 2010
    ..8 ng/mL, which is 30-fold higher than endogenous CSF levels of IL-1Ra. The CSF penetration was not dose-dependent, indicating that the CSF penetration was not saturated in the 3 to 10 mg/kg dose range...
  4. ncbi A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
    Elizabeth Fox
    The Children s Hospital of Philadelphia, Division of Oncology CTRB4016, 3501 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Clin Oncol 28:5174-81. 2010
    ....